598 



SUBJECT INDEX 



Infective particles, see Viruses 



Infectivity, ribonucleic acid, tobacco 

 mosaic virus and, 441-445 



Infectivity assay, ribonucleic acid, to- 

 bacco mosaic virus and, 437-439 



Infectivity end-point dilution, 350, 351, 

 352, 353 

 definition of, 331 

 limitations of, 331 



Infectivity retention, virus chemical 

 alterations and, 392-398 



Influenza A virus, 2, 4 



ether inactivation and, 413 

 ethylene oxide inactivation and, 412 

 MEL, plaque-count assay of, 337 

 neutralization of, 539 

 PR8 



formaldehyde inactivation and, 401 

 plague-count assay of, 337 

 viscosity data and, 235-236 

 ribonucleic acid and, 5 

 serological differences in, 529-530 

 sodium deoxycholate and, 418 



Influenza B virus 



ethylene oxide inactivation and, 412 

 neutralization of, 539 

 ribonucleic acid and, 5 



Influenza virus, 7-8, 75, 142, 198, 331 

 adsorption of, 342 

 cell surface adsorption of, 10-11 

 chemical composition of, 482-489, 496 

 complement fixation and, 533-534 

 5, 6-dichloro-^-D-ribofuranosyl benzi- 



midazole and, 80 

 dipse phase and, 11 

 filamentous forms of, 345-346, 355 



uorescent antibodies and, 534 

 heat inactivation and, 386, 387 

 hemagglutination and, 344, 345, 346 

 host nucleus need and, 30 

 hydrolase of, 22, 23 

 "incomplete" virus and, 355 

 infectivity titration and, 338 

 local lesion count assay of, 335 

 mercuric chloride and, 417 

 multiplication of, 10, 562 

 neuraminidase and, 7-8, 10, 19-20, 21, 



135 

 neutralization, allantoic cavity and, 

 544-545 



papain inactivation and, 414 

 pH, stability and, 389 

 plaque-count assay of, 336, 346 

 precipitin reaction and, 532-533 

 red cell surface 



electrophoretic mobility and, 12 



neuraminidase and, 12 



receptor gradient and, 12 

 reversible inhibition and, 1 1 

 ribonuclease and, 11 

 ribonucleic acid content of, 4-5, 1 1 

 soluble antigen and, 1 1 

 sonic irradiation and, 362 

 sterilization inactivation and, 383 

 surface inactivation of, 363 

 UV inactivation and, 375, 378 

 visible light inactivation of, 380 

 X-ray inactivation and, 371 

 Inhibition 



hemagglutination and, 543-544 

 induced enzyme biosynthesis and, 148- 



150 

 influenza virus and, 1 1 

 protein synthesis and, 96-97 

 Inhibitors, virus synthesis and, 20 

 Insect inclusion body proteins, amino 



acid composition of, 512 

 Insect viruses, 27 



chemical composition of, 513-521 

 deoxyribonucleic acid, purine, pyrimi- 



dine composition of, 515 

 inclusion bodies 



physicochemical properties of, 507- 

 510 



protein chemical composition of, 

 510-513 

 insect host, chemical changes in, 505- 



507 

 multiplication of, 563 

 Interference, viruses and, 11 

 lodouracil, polymer synthesis and, 118, 



119 

 Ionic composition, viral inactivation and, 



390-391 

 Irradiation 

 high -energy 



virus inactivation and, 294-295 

 ionizing, 364-366 



viral inactivation and, 366-374 

 sonic, viral inactivation and, 361-363 



